From Proteopedia
(Difference between revisions)
proteopedia linkproteopedia link
|
|
| Line 1: |
Line 1: |
| - | [[Image:1qmr.gif|left|200px]] | + | {{Seed}} |
| | + | [[Image:1qmr.png|left|200px]] |
| | | | |
| | <!-- | | <!-- |
| Line 9: |
Line 10: |
| | {{STRUCTURE_1qmr| PDB=1qmr | SCENE= }} | | {{STRUCTURE_1qmr| PDB=1qmr | SCENE= }} |
| | | | |
| - | '''BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G'''
| + | ===BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G=== |
| | | | |
| | | | |
| - | ==Overview==
| + | <!-- |
| - | Human type 1 immediate allergic response symptoms are caused by mediator release from basophils and mast cells. This event is triggered by allergens aggregating preformed IgE Abs bound to the high-affinity receptor (FcepsilonRI) on these cells. Thus, the allergen/IgE interaction is crucial for the cascade leading to the allergic and anaphylactic response. Two genetically engineered forms of the white birch pollen major allergen Bet v 1 with point mutations directed at molecular surfaces have been characterized. Four and nine point mutations led to a significant reduction of the binding to human serum IgE, suggesting a mutation-induced distortion of IgE-binding B cell epitopes. In addition, the mutated allergens showed a decrease in anaphylactic potential, because histamine release from human basophils was significantly reduced. Retained alpha-carbon backbone folding pattern of the mutated allergens was indicated by x-ray diffraction analysis and circular dichroism spectroscopy. The rBet v 1 mutants were able to induce proliferation of T cell lines derived from birch pollen allergic patients. The stimulation indices were similar to the indices of nonmutated rBet v 1 and natural Bet v 1 purified from birch pollen. The ability of anti-rBet v 1 mutant specific mouse IgG serum to block binding of human serum IgE to rBet v 1 demonstrates that the engineered rBet v 1 mutants are able to induce Abs reactive with nonmodified Bet v 1. rBet v 1 mutants may constitute vaccine candidates with improved efficacy/safety profiles for safer allergy vaccination.
| + | The line below this paragraph, {{ABSTRACT_PUBMED_15470071}}, adds the Publication Abstract to the page |
| | + | (as it appears on PubMed at http://www.pubmed.gov), where 15470071 is the PubMed ID number. |
| | + | --> |
| | + | {{ABSTRACT_PUBMED_15470071}} |
| | | | |
| | ==About this Structure== | | ==About this Structure== |
| Line 28: |
Line 32: |
| | [[Category: Allergen]] | | [[Category: Allergen]] |
| | [[Category: Pathogenesis-related protein]] | | [[Category: Pathogenesis-related protein]] |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 06:27:39 2008'' | + | |
| | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 11:39:12 2008'' |
Revision as of 08:39, 28 July 2008
Template:STRUCTURE 1qmr
BIRCH POLLEN ALLERGEN BET V 1 MUTANT N28T, K32Q, E45S, P108G
Template:ABSTRACT PUBMED 15470071
About this Structure
1QMR is a Single protein structure of sequence from Betula pendula. Full crystallographic information is available from OCA.
Reference
Allergy vaccine engineering: epitope modulation of recombinant Bet v 1 reduces IgE binding but retains protein folding pattern for induction of protective blocking-antibody responses., Holm J, Gajhede M, Ferreras M, Henriksen A, Ipsen H, Larsen JN, Lund L, Jacobi H, Millner A, Wurtzen PA, Spangfort MD, J Immunol. 2004 Oct 15;173(8):5258-67. PMID:15470071
Page seeded by OCA on Mon Jul 28 11:39:12 2008
